Evaluating Spectral CT for Cardiotoxicity in Lymphoma Patients Treated with Anthracyclines
Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
This study is testing if a special type of CT scan can help find heart damage early in lymphoma patients who are being treated with certain chemotherapy drugs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06774326 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Spectral CT imaging in detecting acute and chronic cardiac toxicity in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma who are receiving anthracycline-based treatments. By utilizing advanced imaging techniques, the study aims to identify early signs of myocardial damage, such as edema and fibrosis, which are critical for timely cardioprotective interventions. The research focuses on enhancing routine oncological follow-ups with Spectral CT to improve patient outcomes related to cardiac health.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with Hodgkin's lymphoma or diffuse large B-cell lymphoma undergoing anthracycline treatment.
Not a fit: Patients with significant pre-existing cardiovascular conditions or contraindications to CT imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and management of cardiac toxicity in lymphoma patients, potentially improving their long-term cardiac health.
How similar studies have performed: While there is ongoing research in cardiac imaging for cancer patients, the specific application of Spectral CT for this purpose is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines * Age ≥18 years * Informed consent obtained Exclusion Criteria: * Absolute or relative contraindications to CT examination and/or administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \<15-30 ml/min/1.73m²). * Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies). * History of mediastinal radiotherapy.
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Vincenzo Russo, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Vincenzo Russo, MD
- Email: vincenzo.russo@aosp.bo.it
- Phone: +390512144747
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.